We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Hoth Therapeutics and the University of Cincinnati Research Institute (UCRI) in the US have signed a research agreement to conduct critical antimicrobial characterisation studies for the streamlined development of the antibiotic HT-006.